Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer.

Transl Cancer Res · 2019 · PMC8798204 · PMID 35117146

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Another recent study comparing ICI efficacy with or without KRAS mutations showed a trend toward a better ORR and prolonged PFS in KRAS -mutated NSCLC, with increased benefits for a high rate of PD-L1-positive tumor cells ( 6 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.